• Explore /
  • Poster
  • / Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.

Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.

Abstract Poster

Authors

null

Feng Wang

Sun Yat-sen University Cancer Center, Guangzhou, China

Feng Wang , Tian Shu Liu , Xianglin Yuan , Kangsheng Gu , Ying Yuan , Yanhong Deng , Jian-Ming Xu , Yu-Xian Bai , Ying Wang , Wangjun Liao , He-Long Zhang , Feng Bi , Bang-Mao Wang , Zhixiang Zhuang , Huiyan Luo , Rui-hua Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02004769

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4045)

DOI

10.1200/JCO.2018.36.15_suppl.4045

Abstract #

4045

Poster Bd #

234

Abstract Disclosures

Similar Posters

First Author: Atsushi Takeno

First Author: Jifang Gong

First Author: Zhi Peng

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

First Author: Hiroyuki Arai